—
C+
C+ The full Closelook — membership. Open the C+ overview

TG Therapeutics Inc (TGTX) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — TG Therapeutics Inc

TGTX in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
TG Therapeutics is a commercial-stage biopharmaceutical company that develops treatments for diseases driven by B-cells, a type of immune cell. Its approved product, an antibody therapy for relapsing forms of multiple sclerosis, is sold in the United States and other markets. The pipeline behind it includes further antibody and kinase-inhibitor candidates aimed at the same B-cell pathways. The company is based in Morrisville, North Carolina.
Where it sits in the stack
TG Therapeutics has no seat in our index and no place in the AI build-out layers we track; it sits in the wider universe under Healthcare, in the biotechnology industry, and stops there.
Who it is priced against
The diary has no defined peer group for this name; the market often compares it with larger multiple-sclerosis therapies from Novartis and Roche, which target the same B-cell pathway.
Why Closelook tracks it
It is not part of our index and carries no quote history in the diary, but it does carry a Closelook score, with momentum standing out as the module the score currently rests on.
What the diary watches
Whether sales of the approved multiple-sclerosis therapy keep expanding and how the pipeline candidates progress, since that would shift the read beyond the current price momentum.

TG Therapeutics Inc (TGTX) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for TGTX, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

This name carries no Closelook score, so its cohort ranks on trend state — distance to the 50- and 200-day averages — never on a score it does not have.

Compared against TGTX on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 50/100 · S&P 500 fund at 49, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-18
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 97th percentile of the window, +4.9% over 20 sessions. Factor regime → 2026-09-18
  • Sovereign pressure Index 0.07 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-18

FAQ · from the current data · as of 2026-09-19

Quick answers

What is TG Therapeutics Inc (TGTX)?

TG Therapeutics Inc trades as TGTX on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-19.

Is TGTX in a Closelook index?

Not currently — TG Therapeutics Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-19.

Where does TGTX trade against its moving averages?

Uptrend stack intact: Trades +6.4% vs the 50-day and +42% vs the 200-day average, 4.1% below the 52-week high and +112.5% off the 52-week low. Computed from daily closes. As of 2026-09-18 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does TG Therapeutics Inc do?

TG Therapeutics is a commercial-stage biopharmaceutical company that develops treatments for diseases driven by B-cells, a type of immune cell. Its approved product, an antibody therapy for relapsing forms of multiple sclerosis, is sold in the United States and other markets. The pipeline behind it includes further antibody and kinase-inhibitor candidates aimed at the same B-cell pathways. The diary has no defined peer group for this name; the market often compares it with larger multiple-sclerosis therapies from Novartis and Roche, which target the same B-cell pathway.

Where does TG Therapeutics Inc sit in the AI build-out?

TG Therapeutics has no seat in our index and no place in the AI build-out layers we track; it sits in the wider universe under Healthcare, in the biotechnology industry, and stops there. It is not part of our index and carries no quote history in the diary, but it does carry a Closelook score, with momentum standing out as the module the score currently rests on.

What does this page show?

A live price chart with SMA overlays and drawing tools for TGTX, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.